
    
      The purpose of this Phase 1 open-label, non-randomized dose escalation study is to determine
      the maximum tolerated dose (MTD) and characterize the safety and tolerability of Birinapant
      (TL32711) when administered as a 30 minute intravenous infusion once weekly for three weeks
      per repeated 4 week intervals in subjects with refractory solid tumors or lymphoma.
      Additionally study will assess anti-tumor activity, pharmacokinetics, and exploratory
      biomarkers as a measurement of pharmacodynamic effects.
    
  